Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro

Cytostatic drugs, like cisplatin, vincristine and taxol, when given to cancer patients may cause peripheral neuropathies. We were interested in the potential neuroprotective effects of neurotrophic factors against such neuropathies. To this aim we studied the effects of these cytostatic agents on sensory fibers located in the dorsal root ganglia (DRG) in vitro and studied whether nerve growth factor (NGF) could reverse the cytostatic induced morphological changes on intact DRG (1 DRG/well, n = 10 per dose). Neuritogenesis from DRG was measured with an image analysis system following exposure to different concentrations of cytostatic drugs in the presence of 3 ng NGF/ml and cytosine arabinoside (Ara-C, 10(-6) M). Relative neurite outgrowth in intact DRG in culture was reduced dose-dependently, (a) by vincristine starting at a dose of 0.4 ng/ml for 2 days (-33% as compared to control; P < 0.001, Student's t-test); (b) by taxol 10 ng/ml (-60%; P < 0.001), and (c) by cisplatin 3 micrograms/ml (-47%, P < 0.001). Cisplatin also prevented the migration of satellite cells away from the intact DRG along the extending neurites into the well in contrast to control, vincristine, or taxol. To evaluate the neuroprotective potential of NGF in this in vitro cytostatic neuropathy model, we incubated intact DRG with cytostatic agents in combination with increasing amounts of NGF. Neurite outgrowth from DRG treated with vincristine (0.5 ng/ml)+NGF (3 ng/ml) for 2 days was significantly higher (+87%) than after treatment with vincristine + 1 ng NGF/ml (P < 0.001). Neurite outgrowth from DRG treated with taxol (20 ng/ml)+NGF (3 ng/ml) for 2 days was significantly higher (+228%) than after taxol + 1 ng NGF/ml (P < 0.05). Neuritogenesis from DRG treated with cisplatin (2.5 micrograms/ml)+NGF (3 ng/ml) for 2 days was significantly increased (+105%) compared to treatment with cisplatin + 1 ng NGF/ml (P < 0.001). DRG thus appear to be a very suitable model for studying cytostatic drug-induced neuropathies in vitro and NGF has a clear neuroprotective effect on the vincristine-, taxol-, and cisplatin-induced neuropathies in this in vitro model.

[1]  M. Daniels.  THE ROLE OF MICROTUBULES IN THE GROWTH AND STABILIZATION OF NERVE FIBERS , 1975, Annals of the New York Academy of Sciences.

[2]  E. Shooter,et al.  Properties of the β Nerve Growth Factor Receptor of Avian Dorsal Root Ganglia , 1973 .

[3]  J. Arezzo,et al.  Nerve growth factor prevents experimental cisplatin neuropathy , 1992, Annals of neurology.

[4]  Y. Barde,et al.  Binding of brain-derived neurotrophic factor to the nerve growth factor receptor , 1990, Neuron.

[5]  M. Schwab,et al.  Specificity of retrograde transport of nerve growth factor (NGF) in sensory neurons: A biochemical and morphological study , 1975, Brain Research.

[6]  D. Ishii,et al.  Nerve growth factor effects and receptors in cultured human neuroblastoma cell lines , 1982, Journal of neuroscience research.

[7]  P. Ernfors,et al.  Colocalization of NGF binding sites, trk mRNA, and low-affinity NGF receptor mRNA in primary sensory neurons: responses to injury and infusion of NGF , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  S. Legha,et al.  Vincristine Neurotoxicity , 1986, Medical toxicology.

[9]  M. Barbacid,et al.  Expression of the trk proto-oncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development. , 1990, Genes & development.

[10]  W. Bradley,et al.  The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. , 1970, Journal of the neurological sciences.

[11]  R. Levi‐montalcini,et al.  Essential role of the nerve growth factor in the survival and maintenance of dissociated sensory and sympathetic embryonic nerve cells in vitro. , 1963, Developmental biology.

[12]  M. Barbacid,et al.  The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3 , 1991, Cell.

[13]  N. K. Wessells,et al.  Axon growth: roles of microfilaments and microtubules. , 1970, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Frank,et al.  Neurotrophin 3 supports the survival of developing muscle sensory neurons in culture. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Goeddel,et al.  Neurotrophin-5: A novel neurotrophic factor that activates trk and trkB , 1991, Neuron.

[16]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[17]  L. Belluscio,et al.  Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. , 1990, Science.

[18]  E. Shooter,et al.  Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors , 1985, The Journal of cell biology.

[19]  H. Thoenen,et al.  Physiology of nerve growth factor. , 1980, Physiological reviews.

[20]  N Kumar,et al.  Taxol-induced polymerization of purified tubulin. Mechanism of action. , 1981, The Journal of biological chemistry.

[21]  D Grob,et al.  Vincristine treatment of advanced cancer: a cooperative study of 392 cases. , 1973, Cancer research.

[22]  J Parness,et al.  Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.

[23]  R. Lipton,et al.  Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Greene,et al.  Nerve growth factor regulates both the phosphorylation and steady-state levels of microtubule-associated protein 1.2 (MAP1.2) , 1988, The Journal of cell biology.

[25]  M. Arcila,et al.  cis-diamminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics. , 1992, Toxicology and applied pharmacology.

[26]  S. Crain,et al.  Nerve growth factor attenuates neurotoxic effects of taxol on spinal cord-ganglion explants from fetal mice. , 1982, Science.

[27]  P Bernd,et al.  Association of 125I-nerve growth factor with PC12 pheochromocytoma cells. Evidence for internalization via high-affinity receptors only and for long-term regulation by nerve growth factor of both high- and low-affinity receptors. , 1984, The Journal of biological chemistry.

[28]  R. Stach,et al.  Decrease in the number of lower affinity (type II) nerve growth factor receptors on embryonic sensory neurons does not affect fiber outgrowth , 1982, Journal of neuroscience research.

[29]  J. Heimans,et al.  A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy. , 1992, Archives of neurology.

[30]  H. Thoenen,et al.  Nerve growth factor in sympathetic ganglia and corresponding target organs of the rat: correlation with density of sympathetic innervation. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Crain,et al.  Enhanced Dependence of Fetal Mouse Neurons on Trophic Factors after Taxol Exposure in Organotypic Cultures , 1984 .

[32]  A. Windebank,et al.  Characteristics of Neurite Outgrowth from Rat Spinal Ganglia: Effects of Serum and Segmental Level , 1986, Journal of neuropathology and experimental neurology.

[33]  Michael P. Sheetz,et al.  Single microtubules from squid axoplasm support bidirectional movement of organelles , 1985, Cell.

[34]  S. Horwitz,et al.  Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol , 1983, Neuroscience.

[35]  A. Ross,et al.  Gene transfer and molecular cloning of the human NGF receptor. , 1986, Science.

[36]  R. Lipton,et al.  Taxol produces a predominantly sensory neuropathy , 1989, Neurology.

[37]  R. Levi‐montalcini.  The nerve growth factor: its mode of action on sensory and sympathetic nerve cells. , 1966, Harvey lectures.

[38]  M. Kirschner,et al.  Regulation of microtubule protein levels during cellular morphogenesis in nerve growth factor-treated PC12 cells , 1988, The Journal of cell biology.

[39]  L. Greene,et al.  Regulation of microtubule composition and stability during nerve growth factor-promoted neurite outgrowth , 1986, The Journal of cell biology.

[40]  H. Thoenen,et al.  Retrograde axonal transport of nerve growth factor: specificity and biological importance , 1975, Brain Research.

[41]  S. Horwitz,et al.  Microtubule arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures , 1981, Brain Research.

[42]  K. Herrup,et al.  Characteristics of the retrograde axonal transport system for nerve growth factor in the sympathetic nervous system. , 1974, Brain research.

[43]  Michael P. Sheetz,et al.  Organelle, bead, and microtubule translocations promoted by soluble factors from the squid giant axon , 1985, Cell.

[44]  M. Bothwell,et al.  Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons , 1992, Neuron.

[45]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[46]  G. Sobue,et al.  Gene expression of high- (p140 trk ) and low-affinity nerve growth factor receptor (LNGFR) in the adult and aged human peripheral nervous system , 1993, Neuroscience Letters.

[47]  R. Levi‐montalcini,et al.  The nerve growth factor 35 years later. , 1987, Science.

[48]  J. Arezzo,et al.  Nerve growth factor prevents toxic neuropathy in mice , 1991, Annals of neurology.

[49]  H. Thoenen,et al.  Molecular cloning and expression of brain-derived neurotrophic factor , 1989, Nature.

[50]  P. M. L. Quesne,et al.  Vincristine neuropathy. Clinical and electrophysiological observations. , 1973, Brain : a journal of neurology.

[51]  P. Distefano,et al.  trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor , 1991, Cell.